Silverfin false false 31/05/2024 01/06/2023 31/05/2024 Mrs A Miles 22/05/2018 Dr R Miles 22/05/2018 28 February 2025 The principal activity of the Company during the financial year was that of a dormant company. 11374437 2024-05-31 11374437 bus:Director1 2024-05-31 11374437 bus:Director2 2024-05-31 11374437 2023-05-31 11374437 core:CurrentFinancialInstruments 2024-05-31 11374437 core:CurrentFinancialInstruments 2023-05-31 11374437 core:ShareCapital 2024-05-31 11374437 core:ShareCapital 2023-05-31 11374437 core:RetainedEarningsAccumulatedLosses 2024-05-31 11374437 core:RetainedEarningsAccumulatedLosses 2023-05-31 11374437 core:OfficeEquipment 2023-05-31 11374437 core:OfficeEquipment 2024-05-31 11374437 bus:OrdinaryShareClass1 2024-05-31 11374437 2023-06-01 2024-05-31 11374437 bus:FilletedAccounts 2023-06-01 2024-05-31 11374437 bus:SmallEntities 2023-06-01 2024-05-31 11374437 bus:AuditExemptWithAccountantsReport 2023-06-01 2024-05-31 11374437 bus:PrivateLimitedCompanyLtd 2023-06-01 2024-05-31 11374437 bus:Director1 2023-06-01 2024-05-31 11374437 bus:Director2 2023-06-01 2024-05-31 11374437 core:OfficeEquipment core:TopRangeValue 2023-06-01 2024-05-31 11374437 2022-06-01 2023-05-31 11374437 core:OfficeEquipment 2023-06-01 2024-05-31 11374437 bus:OrdinaryShareClass1 2023-06-01 2024-05-31 11374437 bus:OrdinaryShareClass1 2022-06-01 2023-05-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 11374437 (England and Wales)

MILES MEDICAL LIMITED

Unaudited Financial Statements
For the financial year ended 31 May 2024
Pages for filing with the registrar

MILES MEDICAL LIMITED

Unaudited Financial Statements

For the financial year ended 31 May 2024

Contents

MILES MEDICAL LIMITED

BALANCE SHEET

As at 31 May 2024
MILES MEDICAL LIMITED

BALANCE SHEET (continued)

As at 31 May 2024
Note 2024 2023
£ £
Fixed assets
Tangible assets 3 0 208
0 208
Current assets
Debtors 4 186 1,261
186 1,261
Creditors: amounts falling due within one year 5 ( 3,131) ( 2,994)
Net current liabilities (2,945) (1,733)
Total assets less current liabilities (2,945) (1,525)
Net liabilities ( 2,945) ( 1,525)
Capital and reserves
Called-up share capital 6 2 2
Profit and loss account ( 2,947 ) ( 1,527 )
Total shareholders' deficit ( 2,945) ( 1,525)

For the financial year ending 31 May 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Miles Medical Limited (registered number: 11374437) were approved and authorised for issue by the Board of Directors on 28 February 2025. They were signed on its behalf by:

Mrs A Miles
Director
MILES MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 May 2024
MILES MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 May 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Miles Medical Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Ezenridge Farm, Bere Alston, Yelverton, PL20 7ET, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the company and rounded to the nearest £.

Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a reducing balance basis over its expected useful life, as follows:

Office equipment 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 0 0

3. Tangible assets

Office equipment Total
£ £
Cost
At 01 June 2023 1,492 1,492
At 31 May 2024 1,492 1,492
Accumulated depreciation
At 01 June 2023 1,284 1,284
Charge for the financial year 208 208
At 31 May 2024 1,492 1,492
Net book value
At 31 May 2024 0 0
At 31 May 2023 208 208

4. Debtors

2024 2023
£ £
Corporation tax 0 322
Other debtors 186 939
186 1,261

5. Creditors: amounts falling due within one year

2024 2023
£ £
Other creditors 3,131 2,994

6. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
2 Ordinary shares of £ 1.00 each 2 2